Drug Type CIR-NK |
Synonyms NKL 013, NKL013 |
Target |
Action modulators |
Mechanism HLA-G modulators(major histocompatibility complex, class I, G modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Discovery | United States | 01 May 2025 |